Clinical Trial Update: Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicating completion of a cannabinoid receptor CB1 agonist treatment study for severe chronic anorexia nervosa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anorexia Nervosa

Drugs mentioned

• CB1 agonist

Snippet

Sponsor: Odense University Hospital | Conditions: Anorexia Nervosa | Phase 3 | Status: COMPLETED